Restoring a Vintage Camper? Beware of These Hazards – GearJunkie

Restoring a vintage camper can be a great DIY project and a good way to own an off-grid vehicle on a budget. But beware of these hazards when restoring a camper trailer.

As more people begin to camp and fall in love with affordable, easygoing outdoor vacations, many will upgrade from tent camping to a travel trailer. However, when they see the price tag of a brand new trailer, its likely theyll look to cost-effective alternatives such as restoring a vintage camper.

There are a plethora of resources out there for restoring an old travel trailer. However, these do-it-yourself guides overlook some of the hazards that come with vintage camper restoration projects.

Things such as carbon monoxide, asbestos, and water damage can pose serious health risks if not dealt with properly. Its important to know some of the most dangerous hazards before one dives into a restoration. Cutting corners is never worth risking the safety and health of yourself and those around you.

One of the most common hazards in campers is carbon monoxide (CO). Although this may not be an issue during the restoration process, it can be deadly while camping. Each year, at least 500 people die of carbon monoxide poisoning in RVs and campers.

Some signs of CO poisoning include dizziness, nausea, intense headache, confusion, and sleepiness. When you undertake a restoration project, its paramount to ensure that CO-emitting appliances are properly functional.

The most common cause of CO poisoning in campers derives from equipment failure. Usually, exhaust from a campers generator that leaks into the living quarters is the culprit.

Thoroughly inspect any exhaust pipes. If broken, repair them before use. If the generator is housed in a storage compartment, its imperative there are no leaks into the living quarters. Campers should avoid generator use while asleep, if possible.

Another cause of CO poisoning can come from the exhaust of nearby vehicles. While camping in close quarters, this poses even more of a risk. Never allow vehicles to idle unattended, especially if you plan to remain inside your camper.

One other common source of CO gas build up in campers and RVs is propane gas appliances that are unvented or faulty. A buildup of liquid propane (LP) gas poses a risk not only for CO poisoning but also a risk of explosion.

Propane lines can easily succumb to dry rot when stored for long periods of time and not inspected, especially on vintage trailers and RVs that have not been used for several years. LP gas is heavier than air and will sink as low as it can. That means that tanks stored inside the camper or RV there should always have a vent at the lowest point.

Its pertinent to make sure all CO-emitting equipment is up to date when you restore your vintage trailer. Not only during the restoration process is this important, but one should have propane systems, generators, and appliances inspected annually by a certified RV technician.

Regularly replacing old propane and CO detectors is beneficial in avoiding CO poisoning as well. Always make sure they are functional and install them in the proper places. Because propane is heavier than air, the detector should be installed at the baseboard level. Carbon monoxide detectors are often paired with smoke detectors, which you should also have in your camper.

One of the best parts of buying a vintage camper or RV to restore is the ability to completely redo the interior. You cant go out and buy a brand-new travel trailer with a customized interior without spending a fortune. By gutting and redoing the interior of a vintage camper, the options are endless. However, removing old parts and pieces comes with its own dangers. Restorers should be prepared to protect themselves against exposure to harmful substances and know what to look for.

Before asbestos was partly banned in the United States in the 1980s, it was used in many building products. Asbestos is a group of silicate minerals that can cause mesothelioma, lung cancer, and asbestosis. When breaking up tile, asbestos can easily become trapped in the abdomen if inhaled or ingested and lead to the development of peritoneal mesothelioma. With mesothelioma usually having a life expectancy of 12-21 months after diagnosis, exposure to asbestos is nothing to take lightly.

Typically, you will remove the floor and any old tile when restoring a camper. Old vinyl tile often becomes worn and dull after years of use. Both the tile and adhesive could contain asbestos if the camper is older than 1980.

Asbestos could also be present in loose-fill insulation. Although batt-style insulation is most common in campers, take precautions against inhaling this material.

If your vintage camper is large enough to be equipped with drum brakes, take care if you perform a brake job yourself. Brake pads and shoes often contained asbestos because of its incredible heat resistance and strength.

To mitigate your risk of inhaling or ingesting asbestos, one should wear a high-quality organic respirator and Tyvek suit during the demolition phase. Its also important to double bag asbestos-containing products in a minimum of 6mm plastic. Before leaving the worksite, remove the Tyvek suit. Immediately wash clothing that was worn, and shower to reduce the chances of asbestos fibers embedding themselves into furniture or other household items.

Another important part of any restoration project is inspecting for water damage. Travel trailers, both vintage and brand new, are known for springing leaks. Even the smallest leak can result in an immense amount of damage to the structure of the camper. If left unrepaired, this could cause the camper to collapse in on itself.

Possibly more dangerous is the presence of mold. Mold loves moisture, and if water has penetrated the camper shell, you can be certain mold wont be far behind.

Once youve torn out the walls and old insulation in your camper, carefully inspect the wood framing for damage. If any soft spots, black spots, or wet spots are present, you will need to repair them. You can do so by removing the old framing and replacing it with new material. You can sister the new framing to any old framing that hasnt succumbed to damage.

However, you should remain cautious to make sure the new framing is strong and structurally sound. If youre not sure how to do so, its important to seek professional help in reframing your camper.

You can remediate mold in a multitude of ways. The first step is to discard any porous material with mold such as cloth or carpet. You can attempt to get rid of mold with white vinegar, but often bleach and soapy water will be the best solution. If the mold is resilient to these treatments on wood framing or interior features, they may need to be removed entirely.

If mold is present, it will certainly need to be dealt with. By allowing mold to grow, you risk serious health side effects. Mold can cause wheezing, coughing, and itchy eyes. With prolonged exposure, mold can also cause more severe chronic lung illnesses from infection.

Now that you have your vintage camper clean from harmful toxins, customized, and freshly painted, its finally time to take it out on the road. Once you have your camper, it will be hard to not want to take it out right away. However, getting out for a weekend at camp isnt worth the risk of lifelong or life-ending hazards that should be dealt with first.

A vintage camper should be something that fills you with nostalgia and joy not itchy eyes and wheezing. Take the time to restore your vintage camper safely and properly so you can enjoy it for years to come.

Continue reading here:

Restoring a Vintage Camper? Beware of These Hazards - GearJunkie

ONCOS-102 and Keytruda: A Pairing That Could Cure Mesothelioma – Mesothelioma Guide

The mesothelioma study weve been waiting for is finally going to happen.

Targovax, the manufacturer of the complex ONCOS-102, is teaming with the maker of the well-known immunotherapy drug Keytruda for a clinical trial. The phase 2 study is explicitly using ONCOS-102 and Keytruda for people with pleural mesothelioma.

The trial, which will enroll up to 100 patients, tests a combination of Keytruda, ONCOS-102 and standard chemotherapy. Targovax, which is based in Norway, said the study will involve United States locations.

The aim is to start enrolling patients into the trial within 12 months, the companys press release reads.

If youre interested in participating, reach out to our medical staff. Our patient advocate Jenna Campagna can help you apply for this or other clinical trials. There is no fee to reach out and explore your treatment options. Please contact her via email at jenna@mesotheliomaguide.com.

Researchers believe combining ONCOS-102 and Keytruda will make each of them more effective as mesothelioma treatments. Both are used to help the immune system fight mesothelioma. The therapies just go about their aid in different ways.

ONCOS-102 is a combination of virotherapy and immunotherapy. Its an adenovirus that transmits immune-stimulating proteins into the body. The adenovirus breaks up the tumor cells, and the proteins signal for help to the T-cells.

When the tumor cells break apart, they release antigens into the disease environment. These antigens serve as fingerprints, which helps T-cells to locate other tumors.

In a recent mesothelioma study, ONCOS-102 was paired with standard chemotherapy. Researchers compared its effects to just using chemotherapy. ONCOS-102 plus chemotherapy showed across-the-board benefits:

Keytruda, the brand name for the immunotherapy drug pembrolizumab, is an immune checkpoint inhibitor. It blocks cancerous proteins that suppress the immune system. Keytruda stops PD-L1 (cancer protein) from communicating with PD-1 (immune system T-cell protein). Doing so allows the T-cells to attack tumors.

Keytruda recently received approval from the U.S. Food and Drug Administration for limited use in treating pleural mesothelioma. The FDA granted permission for cases with a high level of PD-L1 protein expression, as research has shown that Keytruda helps these patients.

The combination of Keytruda and ONCOS-102 makes sense. ONCOS-102s primary goal is to get T-cells into the tumor environment. Keytruda will help those T-cells register mesothelioma cells as dangerous.

Keytruda is the market-leading checkpoint inhibitor and thus our preferred choice of partner, said ystein Soug, the CEO of Targovax. We are hopeful that the combination will lead to improved outcomes for patients with this challenging disease who currently have few treatment alternatives.

Targovax is testing ONCOS-102 with an immunotherapy drug for peritoneal mesothelioma patients as well. The company is hosting a phase 2 clinical trial that combines ONCOS-102 with durvalumab, which is also a PD-L1 inhibitor therapy.

Show Sources & Author

Devin Golden is the content writer for Mesothelioma Guide. He produces mesothelioma-related content on various mediums, including the Mesothelioma Guide website and social media channels. Devin's objective is to translate complex information regarding mesothelioma into informative, easily absorbable content to help patients and their loved ones.

Get in depth knowledge about your diagnosis & the best treatments.

Learn More

See the rest here:

ONCOS-102 and Keytruda: A Pairing That Could Cure Mesothelioma - Mesothelioma Guide

Mesothelioma Compensation Center Urges the Family of a Power Plant Worker with Recently Diagnosed Mesothelioma to Call Attorney Erik Karst of Karst…

HOUSTON, July 29, 2020 /PRNewswire/ -- The Mesothelioma Compensation Center says, "We are appealing to the family of a power plant worker nationwide who has just been diagnosed with mesothelioma to please call 800-714-0303 for direct access to attorney Erik Karst of the law firm of Karst von Oiste. Erik Karst and his colleagues at Karst von Oiste have been assisting power plant workers for decades and they are responsible for over a billion dollars in financial compensation results for people like this.

"Financial compensation for a power plant worker with this rare cancer caused by asbestos exposure might exceed a million dollars-if the person or family hires an experienced mesothelioma lawyer. Erik Karst is one of the nation's leading mesothelioma attorneys-and he will know how to help you or your loved one."www.karstvonoiste.com

The Mesothelioma Compensation Center is also urging the wife or adult son-daughter of a former power plant worker who had heavy to extreme exposure to asbestos at work to please tell their doctors about his work place exposure to asbestos if he has been hospitalized with pneumonia. Mesothelioma and the Coronavirus have similar symptoms such as pneumonia, high fever, and shortness of breath.

They say, "The average age for a person with mesothelioma in the United States is 72 years old. Mesothelioma could easily be misdiagnosed as the Coronavirus. We do not want a person with mesothelioma to not get compensated in 2020 because they were misdiagnosed with the Coronavirus. If your husband or dad is in the hospital right now with pneumonia and you know for a fact he had significant exposure to asbestos at work-before 1982 please call us at 800-714-0303 so we might try to assist in ensuring a proper diagnosis-if possible."https://MesotheliomaCompensationCenter.Com

The Mesothelioma Compensation Center is Extremely Focused on Helping the Following Types of People with Mesothelioma:

For more information about power plants inthe United Statesplease refer to the US Energy Information Agency's website: https://www.eia.gov/ state/maps.php.

The Mesothelioma Compensation Center specializes in assisting specific types of people who have been diagnosed with mesothelioma. The Center's top priority is assisting US Navy Veterans, shipyard workers, oil refinery workers, public-utility workers, chemical plant workers, manufacturing workers, power plant workers, plumbers, welders, electricians, millwrights, pipefitters, boiler technicians, machinists, nuclear power plant workers, hydro-electric workers or oil and gas field production workers who have been diagnosed with this rare cancer caused by asbestos exposure. In most instances a diagnosed person with mesothelioma was exposed to asbestos in the 1950's, 1960's, 1970's, or 1980's.https://MesotheliomaCompensationCenter.Com

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

However, a power plant or public utility worker with mesothelioma could live in any state including California, New York, Florida, Texas, Illinois, Kentucky, Tennessee, Mississippi, Georgia, Alabama, Wyoming, Colorado, New Mexico, Nevada, Utah, Arizona, Idaho, or Alaska.www.karstvonoiste.com/

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer:https://www.cancer.gov/types/mesothelioma.

Media Contact:Michael Thomas800-714-0303241211@email4pr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/mesothelioma-compensation-center-urges-the-family-of-a-power-plant-worker-with-recently-diagnosed-mesothelioma-to-call-attorney-erik-karst-of-karst-von-oiste-for-his-passion-the-best-client-compensation-results-301101967.html

SOURCE Mesothelioma Compensation Center

Read the original:

Mesothelioma Compensation Center Urges the Family of a Power Plant Worker with Recently Diagnosed Mesothelioma to Call Attorney Erik Karst of Karst...

Alabama US Navy Veterans Mesothelioma Advocate Has Endorsed Attorney Erik Karst of Karst von Oiste To Make Certain a Navy Veteran with Mesothelioma in…

(MENAFN - EIN Presswire)

MONTGOMERY , ALABAMA, USA, August 4, 2020 / EINPresswire.com / -- The Alabama US Navy Veterans Mesothelioma Advocate says, "We have endorsed, and we recommend attorney Erik Karst of the law firm of Karst von Oiste if you are a Navy Veteran with recently diagnosed mesothelioma in Alabama or their family. Erik Karst is one of the nation's leading mesothelioma attorneys and he specializes in financial compensation for US Navy Veterans who have this rare form of cancer caused by asbestos exposure. Financial compensation for a Navy Veteran with mesothelioma might exceed a million dollars. If the Navy Veteran spent a career in the navy the compensation might be in the millions. For direct access to attorney Erik Karst of Karst von Oiste please call 800-714-0303 anytime." [To enable links contact MENAFN]

The Advocate is also appealing to the wife, or adult son-daughter of a Navy Veteran with mesothelioma in Alabama to call Erik Karst of Karst von Oiste at 800-714-0303 to assist in building the foundation for the veteran's mesothelioma claim. There are Internet ads that suggest, 'no lawsuits' needed which is a stretch of the truth. In reality-if a Navy Veteran with mesothelioma or their family hires a local car accident attorney the Veteran or their family might get significantly shortchanged-out of hundreds of thousands of dollars or more. Rather than roll the dice on financial compensation for a Navy Veteran with mesothelioma please call 800-714-0303 for direct access to attorney Erik Karst of Karst von Oiste. [To enable links contact MENAFN]

The US Navy Veterans Mesothelioma Advocate offers their free services to US Navy Veterans with mesothelioma in Birmingham, Montgomery, Mobile, Huntsville, Tuscaloosa or anywhere in Alabama. [To enable links contact MENAFN]

For the best possible treatment options in Alabama the Alabama US Navy Veterans Mesothelioma Advocate strongly recommends the following heath care facility with the offer to help a diagnosed Veteran, or their family get to the right physicians at these hospitals.

The University of Alabama's Comprehensive Cancer Center in Birmingham. [To enable links contact MENAFN] .

About one third of all US citizens diagnosed with mesothelioma each year are Veterans of the US Navy. Before a Navy Veteran with mesothelioma or their family retain the services of a lawyer or law firm, they are urged to call the US Navy Veterans Mesothelioma Advocate anytime at 800-714-0303. [To enable links contact MENAFN]

The states with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

However, based on the calls the US Navy Veterans Mesothelioma advocate receives a US Navy Veteran diagnosed with mesothelioma could live in any state including New York, Florida, California, Texas, New Hampshire, Vermont, Iowa, Indiana, Missouri, Kentucky, Tennessee, North Carolina, Georgia, Alabama, Mississippi, Oklahoma, Arkansas, Nebraska, North Dakota, Montana, Wyoming, Nevada, New Mexico, Utah, Arizona, Idaho, or Alaska. [To enable links contact MENAFN]

For a listing of various classes of US Navy ships or submarines please visit the US Navy website on this topic: [To enable links contact MENAFN] .

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer: [To enable links contact MENAFN] .

Michael ThomasAlabama US Navy Veterans Mesothelioma Advocate+1 800-714-0303email us here

See the original post here:

Alabama US Navy Veterans Mesothelioma Advocate Has Endorsed Attorney Erik Karst of Karst von Oiste To Make Certain a Navy Veteran with Mesothelioma in...

Mesothelioma treatment Market Insight And Key Players With Forecasts Up To 2028 – WOLE TV

Global Mesothelioma treatment Market presents an in-depth review and technical research, with useful facts and figures, of the current and future state of the mesothelioma treatment market worldwide. mesothelioma treatment market provides information on emerging market opportunities and business factors, developments and evolving technologies that will fuel these growth trends. The report provides a comprehensive overview including Comparison of Definitions, Range, Use, Production and CAGR (percent), Form Segmentation, Share, Revenue Status and Outlook, Capacity, Demand, Market Drivers, Production Status, and Outlook and Opportunities, Export, Import, Growth Rate for Emerging Markets / Countries. The study provides a 360-degree overview of the industrys competitive landscape. The industry study on mesothelioma treatment assesses the main regions (countries) promising a huge market share for the 2016-2028 forecast period.

The market research study on mesothelioma treatment was collected through comprehensive primary research through interviews, surveys, and findings of experienced analysts and secondary research. The study also provides a complete qualitative and quantitative assessment by analyzing data obtained from industry analysts and market participants from mesothelioma treatment around key points in the value chain of the industry.

The regional analysis of this report covers the following regions- Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Ono Pharmaceutical Co. Ltd, Bayer AG, Teva Pharmaceuticals Industries Ltd.

Get Sample Copy of The Report @ https://www.quincemarketinsights.com/request-sample-68793?utm_source=Kalpesh&utm_medium=WTV

Useful findings of this research are-

-Study of historical data.

-Analysis of existing scenarios in every domestic and national sector.

-Study of patterns, accessible knowledge and data figures.

-Use of validated project methods for the next five years.

Statistical analysis, figures and prime data included in the report contains-

-Market size (current and projected for the last few years)

-Market share analysis as per different companies)

-Market forecast)

-Demand)

-Price analysis)

-Market contributions (Size, Share according to geographical boundaries)

The report benefits Market Investigators, companies, Vendors, Buyers, Suppliers, Individual professionals and Competitive organizations

Make An Enquiry Before Purchasing Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-68793?utm_source=Kalpesh&utm_medium=WTV

Market Segmentation:

ByTreatment Type:

By Route of Administration:

ByDistribution Channel:

By End User:

By Region:

North AmericaMesothelioma treatment market

EuropeMesothelioma treatment market

Asia PacificMesothelioma treatment market

Middle East & AfricaMesothelioma treatment market

South AmericaMesothelioma treatment market

Contact:Quince Market InsightsOffice No-A109Pune, Maharashtra 411028Phone: +91-9850603687/7972869557Email: sales@quincemarketinsights.comWeb: http://www.quincemarketinsights.com

About :QMI has the most comprehensive collection of market research products and services available on the web. Deliver reports from almost all major publications and update the list on a regular basis with instant online access to the worlds broadest and most up-to-date archive of expert insights on global markets, companies, products and patterns.

Read the original post:

Mesothelioma treatment Market Insight And Key Players With Forecasts Up To 2028 - WOLE TV

Compensation claim after ICI worker’s asbestos-related death – Runcorn and Widnes World

THE death of a loving grandfather from an asbestos-related lung cancer has led to his family launching a compensation claim.

Sandiway native Christopher Lees worked for ICI in Northwich and Runcorn for close to 40 years, after leaving school in 1955 until his retirement in the early 1990s.

In February, he was diagnosed with mesothelioma an aggressive and terminal lung cancer caused by breathing in asbestos dust and fibres and sadly passed away on May 17 aged 79.

A father of two daughters and grandfather of four, Christopher was also the main carer for his wife, Gillian, who has a lung condition and severe arthritis.

He was a regular and respected church goer, but his family were unable to give him a proper funeral because of coronavirus restrictions.

Despite this and the severely restricted numbers allowed at his burial, that did not stop his family, friends and parishioners from lining the funeral route on the day to send him off.

It is believed that he was exposed to asbestos while working at ICI in Winnington and the companys Castner Kellner site in Runcorn.

Nicola Johnson, Christophers daughter, said: In just six months, dad went from helping me with the school run and being Mums fulltime carer to not being here at all.

He just deteriorated so fast and was in a huge amount of pain constantly at the end.

I remember taking him to get the results of his biopsy. We sat there holding hands, both expecting bad news, as we didnt think wed be lucky enough to get away with it. Devastatingly, we were right.

He was really upset and so scared in the car on the journey home. He told me what his wishes were and how we were going to cope with it."

Christopher receiving his 20-year service award

We were told he could have chemotherapy to extend his life, and for the next two weeks hed pick himself up and push himself to go out for walks to keep himself fit to be ready to face what was coming next.

Then Covid-19 hit, and all bets were off.

Birchall Blackburn Law is helping Christophers family make an industrial disease compensation claim and is seeking the memories and recollections from former ICI employees.

Christopher started in the research and development department and from 1968 to 1975 worked on the development of Monnex, which required him to wear an asbestos suit.

In 1975 Christopher moved to ICIs Castner Kellner site to work as a safety advisor, improving working conditions and reducing the risk of accidents and injuries.

In 1988/89 Christopher returned to work at Winnington and Lostock sites as a safety advisor.

Victoria Roberts, an industrial disease specialist solicitor at Birchall Blackburn Law, said: Mesothelioma is a cruel lung cancer that takes decades to develop after exposure to asbestos dust and fibres.

It can be difficult to find evidence about where exactly the exposure took place, which is why we need the help of former ICI employees who worked in Northwich and Runcorn.

We would be interested to hear from anyone who worked in the research and development department at Winnington and might be able to assist with a description of the fire suits used, as well as anyone who worked at Castner Kellner and can provide information about the maintenance procedure and the use and presence of asbestos on site.

Anyone who knows about the presence of asbestos at ICI in Northwich and Castner Kellner in Runcorn is asked to call Victoria confidentially on 01244 688763 or email varoberts@birchallblackburn.co.uk

See the original post:

Compensation claim after ICI worker's asbestos-related death - Runcorn and Widnes World

Pennsylvania Mesothelioma Victims Center Urges the Family of a Person with Recently Diagnosed Mesothelioma in Pennsylvania to Please Call Attorney…

(MENAFN - EIN Presswire)

PITTSBURGH , PENNSYLVANIA , USA, August 3, 2020 / EINPresswire.com / -- The Pennsylvania Mesothelioma Victims Center says, "We are urging the wife or adult son-daughter of a person who has just been diagnosed with mesothelioma anywhere in Pennsylvania to insist on much better financial compensation results and to call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303 to get the job done. To get the best possible mesothelioma compensation it is vital a person with mesothelioma hire lawyers that know what they are doing. Erik Karst is one of the nation's leading mesothelioma lawyers and he will know how to help a person with this rare cancer caused by asbestos exposure in Pennsylvania.

"Because Pennsylvania was hit hard by the Coronavirus there is a good chance a person with mesothelioma was initially diagnosed this virus. If and when-the doctors figured out that the person had mesothelioma as opposed to the Coronovirus a couple of months were lost as far as proper treatment.

"If this sounds like you or your loved one and the mesothelioma has been confirmed please call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303 to get the compensation process moving. Erik and his colleagues at Karst von Oiste have been assisting people with mesothelioma for decades and they are responsible for over a billion dollars in financial compensation for people like this. The average age of a person with mesothelioma is about 72 years old. Please don't roll the dice on mesothelioma compensation." [To enable links contact MENAFN]

The Pennsylvania Mesothelioma Victims Center wants to emphasize their services for a person with mesothelioma or asbestos exposure lung cancer are available throughout the state of Pennsylvania including communities such as Philadelphia, Pittsburgh, Allentown, Eire, Upper Darby, Reading, Scranton, or Bethlehem.

[To enable links contact MENAFN]

For the best possible treatment options in Pennsylvania we strongly recommend the following two heath care facilities with the offer to help a diagnosed victim, or their family get to the right physicians at each hospital.

* Penn's Abramson Cancer Center in Philadelphia: [To enable links contact MENAFN] .

* University of Pittsburgh Cancer Institute: [To enable links contact MENAFN]

High risk work groups for exposure to asbestos in Pennsylvania include US Navy Veterans, power plant workers, shipyard workers, oil refinery workers, steel mill workers, coal miners, manufacturing workers, plumbers, electricians, welders, pipefitters, insulators, boiler technicians, auto mechanics, machinists, or construction workers. Typically, the person's exposure to asbestos occurred in the 1950's, 1960's, 1970's, or 1980's. [To enable links contact MENAFN]

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, California, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. [To enable links contact MENAFN]

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer: [To enable links contact MENAFN]

Michael ThomasPennsylvania Mesothelioma Victims Center+1 800-714-0303email us here

Read more from the original source:

Pennsylvania Mesothelioma Victims Center Urges the Family of a Person with Recently Diagnosed Mesothelioma in Pennsylvania to Please Call Attorney...

Asbestos-Related Lung Cancer: Prevention and Awareness – Asbestos.com

Aug. 1 is World Lung Cancer Day, and the American Lung Association is encouraging everyone to educate themselves on environmental risk factors and prevention through early screening.

Lung cancer can affect anyone, and it remains the most common and deadly cancer worldwide. The disease is responsible for approximately one in five deaths globally and accounts for over 2 million cases annually.

Taking steps to avoid exposure to dangerous substances and environmental toxins can substantially decrease the risk of developing lung cancer and other diseases such as mesothelioma.

Smoking causes an overwhelming 80% of lung cancer deaths, but it is essential to recognize other risk factors. Many people diagnosed with the disease never smoked in their lives. Exposure to toxins such as asbestos increases the risk of lung cancer in smokers and non-smokers.

Inhaling asbestos dust causes microscopic fibers to become trapped within the lung tissue. Over several years, asbestos in the lungs causes damage to DNA that results in mutations that produce lung cancer. More commonly, asbestos becomes lodged in the lining surrounding the lungs, causing pleural mesothelioma.

Similar to mesothelioma, asbestos-related lung cancer usually develops around 15 to 35 years after initial exposure. Physicians diagnose most cases in workers who experienced occupational exposure after working with asbestos decades prior.

Lung cancer prevention starts with identifying if you are part of a population at risk for developing the disease. Many employers knowingly exposed their workers to asbestos for decades before regulation became widespread.

Workers in the mining, construction, shipbuilding and firefighting industries are most at risk due to the historical use of asbestos materials in structures and manufacturing. Veterans are also at high risk because of the militarys use of the substance in older bases and ships.

Adults over the age of 55 who are smokers or at risk of asbestos-related lung cancer can take significant preventative measures by undergoing screening.

A new low-dose CT scan is now available, and the Centers for Disease Control and Prevention recommends the scan for older adults with a history of smoking. However, those with a history of possible asbestos exposure should also talk to their doctors about undergoing a low-dose CT.

If more Americans adopt preventative measures against lung cancer, early screening can significantly improve lung cancer survival rates. The American Lung Association estimates low-dose CT scans could save 25,000 lives every year if the 8 million high-risk Americans underwent early screening.

Discussing a potential history of asbestos exposure with your primary care physician is the first step in getting the recommended tests and an accurate diagnosis.

In addition to asbestos exposure, genetics and overall health play a role in the development of lung cancer. Identifying just one risk factor, such as occupational asbestos exposure, can prevent years of lung cancer treatment.

Patients with lung cancer typically experience shortness of breath, chest pain and general fatigue. Symptoms usually only arise once lung cancer has entered its later stages. At that time, lung cancer is more challenging to treat and options are limited.

The CDC recommends people with a history of asbestos exposure seek regular screening for asbestos-related lung cancer. However, there are other environmental sources of lung cancer that might not be common knowledge.

Asbestos-related lung cancer accounts for approximately 4% of all lung cancer deaths. Many Americans may not realize the risk of asbestos in homes. Houses and buildings built before the 1980s are likely to contain asbestos in the insulation, flooring, roofing or other construction materials.

When asbestos-containing materials are damaged, the fibers escape as microscopic particles that pollute the air. Owners of older homes should be aware of asbestos-containing materials used in their houses.

The second-most common cause of lung cancer is also present within the home. Radon is a colorless and odorless gas that is radioactive. It is found in homes and commercial buildings across the U.S. The gas forms naturally in the ground after the radioactive decay of soil and rock.

Radioactive radon particles can become lodged in the lungs and damage cellular tissue, eventually causing cancer. Radon is responsible for approximately 20,000 lung cancer deaths annually, and smokers exposed to radon have a higher risk of developing lung cancer.

The Environmental Protection Agency estimates that one in 15 homes in America has elevated levels of radon gas. Testing for the gas is easily accessible through self-testing kits and recommended for homes with or without basements. Addressing elevated levels of radon can prevent lung cancer for everyone in the household.

Other lesser-known environmental causes of lung cancer include outdoor air pollution, such as engine exhaust, and silica dust resulting from the breakdown of construction materials.

While the dangers of asbestos and smoking are well known, many other factors could put you at a higher risk for lung cancer.

For World Lung Cancer Day, take time to educate yourself and others on simple measures you can take to prevent this deadly illness. Talk to your physician about your familys history of cancer, and test your home for asbestos or radon. Its never too early to start preventative measures that could one day save your life.

Free Mesothelioma ResourcesGet Access to Free Resources for Patients & Loved Ones

Read the original here:

Asbestos-Related Lung Cancer: Prevention and Awareness - Asbestos.com

Mesothelioma Treatment Market Sales, Price, Revenue, Gross Margin and Industry Share 2020 2027 – Owned

The Mesothelioma Treatment Market research report thoroughly explains each and every aspect related to the Global Mesothelioma Treatment Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.

Get Free Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) at: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-mesothelioma-treatment-market

The growth trend forecasted on account of a thorough examination offers in-depth information regarding the Mesothelioma Treatment Market. This global market report offers research and consulting services focused on achieving competitive leverage, with acquiring and preserving market position as key aims of the program.

Prominent Key Players Covered in the report:

Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Ono Pharmaceutical Co. Ltd, Bayer AG, Teva Pharmaceuticals Industries Ltd, GlaxoSmithKline plc, Sun Pharmaceuticals Industries Ltd, Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Services, Inc., AbbVie Inc., Amgen, Inc., and others.

Key Pointers Covered in the Mesothelioma Treatment Market Industry Trends and Forecast to 2027

A complete value chain of the global Mesothelioma Treatment market is presented in the research report. It is associated with the review of the downstream and upstream components of the Mesothelioma Treatment Market. The market is spliton the basis of the categories of products and clientapplication segments. The market analysis demonstrates the expansion of each segment of the global Mesothelioma Treatment market. The research report assists the user in taking a decisive step on the way tobe a milestone ingrowingandexpandingtheirorganizationsinside theworldwideMesothelioma Treatment market.

Major Regions as Follows:

North America (USA, Canada and Mexico)

Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe)

Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, rest of countries etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

How Does This Market Insights Help?

Why choose us:

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-mesothelioma-treatment-market

The report highlights current and future market trends and carries out an analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Mesothelioma Treatment market report include market definition, market segmentation, key developments, competitive analysis and research methodology.

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Market Drivers

Market Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Mesothelioma Treatment Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report Give information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability inspection and venture return investigation.

For More Information or Query or Customization before Buying, Visit at: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-mesothelioma-treatment-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

Read more here:

Mesothelioma Treatment Market Sales, Price, Revenue, Gross Margin and Industry Share 2020 2027 - Owned

Cancer Therapeutics Market to Exhibit Rapid Surge in Consumption in the COVID-19 Crisis 2026 – Market Research Posts

The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026.

Get Access to sample pages @https://www.trendsmarketresearch.com/report/sample/13204

Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.

However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.

Thecancer therapeutics marketis segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS This report entails a detailed quantitative market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market. Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry. An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning. The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

By Applicationo Blood Cancero Lung Cancero Colorectal Cancero Prostate Cancero Breast Cancero Cervical Cancero Head and Neck Cancero Glioblastomao Malignant Meningiomao Mesotheliomao Melanomao Others

By Top Selling Drugso Revlimido Avastino Herceptino Rituxano Opdivoo Gleeveco Velcadeo Imbruvicao Ibranceo Zytigao Alimtao Xtandio Tarcevao Perjetao Temodaro Others

By Regiono North America U.S. Canadao Europe Germany France UK Italy Spain Rest of Europeo Asia-Pacific Japan China India Australia South Korea Taiwan Rest of Asia-Pacifico LAMEA Latin America Middle-East Africa

The list of key players operating in this market include: F. Hoffmann-La Roche AG Bristol-Myers Squibb Company AbbVie, Inc. Johnson & Johnson Celgene Corporation Astellas Pharma, Inc. Pfizer, Inc. Novartis AG Merck KGaA Eli Lilly and Company

The other players included in the value chain analysis (and not included in the report) include: AstraZeneca plc Bayer AG Takeda Pharmaceutical Company Limited

Visit link:

Cancer Therapeutics Market to Exhibit Rapid Surge in Consumption in the COVID-19 Crisis 2026 - Market Research Posts

Prudhoe mum with terminal cancer marries long-term partner after being given months to live – Chronicle Live

A Prudhoe mum with terminal cancer has got married to her long-term partner after being given months to live.

Allison Kelly began suffering from a shortness of breath and a cough with doctors putting them down to being post coronavirus symptoms.

But just two months later she was struggling to breath and was admitted into hospital where she was found to have 4.6 litres of fluid in her left lung.

A biopsy revealed the 55-year-old had mesothelioma - a type of cancer that mainly affects the lining of the lungs - and was given just six to eight months left to live.

The devastating diagnosis prompted Allison's partner of 27 years, Alan Wright, 58, to pop the question.

And within a matter of weeks the couple tied the knot at Hexham House in front of their daughter and bridesmaid Sophie, 17, and Allison's mum and stepdad.

Allison said: "It was after I left the hospital when Alan said 'come on, let's get married'.

"There was no engagement and it all had to be done very quickly. We needed to get married before I started any treatment so I was well enough to enjoy the day.

"It was all done very simply. I had a very old suit on that was given to me by a mum in an antenatal class years ago.

"Alan had an old suit on. It was a very moving service and Alan walked me down the aisle due to the coronavirus restrictions.

"But it was perfect. It was very special day filled with a lot of laughter."

Allison's diagnosis came just 25 years since she beat breast cancer at the age of 29.

It is not the first time cancer has hit her family.

A gene fault has meant she has lost her dad and two sisters to the disease while her half-sister was diagnosed with breast cancer last year.

The archery champion is expected to discover next week if she is eligible to participate in a trial of a drug which is hoped to manage the symptoms of the cancer.

The happy couple had pictures taken in the picturesque gardens of Hexham House before returning to their Prudhoe home where they celebrated into the night.

Allison said: "We had afternoon tea and champagne and it was such a laugh. It makes everything complete. It was so special.

"I'm just really happy. I don't worry about what is going to happen because I don't want to waste my energy on something I can't control.

"It's been hard for Alan and Sophie. We've got to make the most of the time we have left as a family."

Allison admits to being overwhelmed by the generosity of people for helping to make her wedding day so special.

A JustGiving page raised more than 7,400 in total which helped towards the cost while an army of volunteers have completely overhauled the family's back garden free of charge.

She said: "It's been incredible seeing the amount of support we've received from everyone. It has all made a huge difference to my life. Thank you doesn't even feel adequate.

"It has all been such a help, especially during the time when Alan and Sophie were trying to come to terms with everything. We have been very lucky and we're incredibly grateful to everyone."

The rest is here:

Prudhoe mum with terminal cancer marries long-term partner after being given months to live - Chronicle Live

The Impact of COVID-19 on Mesothelioma Research – Mesothelioma.net Blog

Published on July 28, 2020

The global pandemic has had a profound impact on all of our lives, not least of these being the ability for malignant mesothelioma researchers to continue their work. With patients fearful of leaving their homes to come in for treatments or examinations and scientists seeing a shortage of funds (and feeling an obligation to participate in the care of COVID-19 patients,) many fear that innovations will be delayed. But a professor of cancer medicine from the University of Oxford thinks the crisis will bring positive change in the long run.

Those concerned about mesothelioma research can take heart after reading what Professor David Kerr said in an article that appeared inMedscape.A professor of cancer medicine at the highly respected University of Oxford, Kerr acknowledges the hurdles that the COVID-19 pandemic has posed for cancer researchers, but also points to the remarkable ways that patients, physicians and researchers have responded.

Mesothelioma researchers will recognize the truth of what he is saying. In spite of research funding having slowed and staff members having been redeployed and reprioritized, researchers have turned to telemedicine to follow patients. Doing so has kept those vulnerable patients safe while still allowing clinical trial data to be collected.

While HIPAA regulations will require mesothelioma patients to grant authorization for remote consultations and access to their electronic health records, there are ways to ensure that confidentially will be maintained. The need for flexibility may also lead to greater collaboration between different research organizations.

The pandemic has proven that mobile phone apps and telemedicine allow patients to be monitored and supported remotely, giving a sense that clinical trials will still be able to proceed. Though patients will still need to report in person for their treatments, the amount of time that they have to be in the clinic can be cut dramatically, representing a significant improvement in convenience and quality of life, even after the crisis has passed.

If you are a mesothelioma patient who would like more information on participating in a clinical trial, the Patient Advocates at Mesothelioma.net can help. Contact us today at 1-800-692-8608.

Learn more about and contact Terri

Go here to see the original:

The Impact of COVID-19 on Mesothelioma Research - Mesothelioma.net Blog

Mesothelioma Applied Research Foundation to Fund Additional Studies – Mesothelioma.net Blog

Published on July 27, 2020

Though the nation and world are intensely focused on the COVID-19 crisis and finding effective treatments and vaccines, that in no way diminishes the need for continued attention to other challenging illnesses, including malignant mesothelioma. In recognition of the need for innovative new treatments, the Mesothelioma Applied Research Foundation recently announced a continuation of its support of research on this fatal, asbestos-related cancer. The organization will be funding three separate and deserving research projects.

Speaking of the need for more effective treatment options for patients diagnosed with malignant mesothelioma, nurse practitioner and Executive Director of the Meso Foundation Mary Hesdorffer said, We are keenly aware that mesothelioma patients still need effective treatments, first and foremost. We are deeply grateful to all of our donors and supporters who made this funding possible with their financial contributions.

Earlier in the year, the Mesothelioma Applied Research Foundation joined with other charitable organizations that requested that Congressional leaders recognize the challenges of fundraising during the COVID-19 crisis. The group asked that Congress continue funding medical research. The newly announced investment from the 501(c)(3) non-profit totals $300,000, bringing the Meso Foundations funding total to $10.5 million since it began in the year 2000.

The Meso Foundation follows a robust selection process supported by experts in the field of mesothelioma research. Their goal is to fund the most promising studies, reviewing all applications for grants and ranking them through an unbiased peer-review process. The amount of funding available determines the number of projects that will be funded.

The three projects selected were chosen from nearly 50 applications that were narrowed down to eight finalists. Though all three that were selected for funding will examine the impact of immunotherapy on mesothelioma patients, each takes a different approach.

As scientists work to find effective treatments for malignant mesothelioma, the Patient Advocates at Mesothelioma.net are working to support those who are currently afflicted with the disease. For more information on the resources available to you, contact us today at 1-800-692-8608.

Learn more about and contact Terri

The rest is here:

Mesothelioma Applied Research Foundation to Fund Additional Studies - Mesothelioma.net Blog

Mesothelioma Victims Center Has Endorsed Attorney Erik Karst of Karst von Oiste to Make Certain a Steel Mill or Factory Worker with Mesothelioma –…

HOUSTON, July 28, 2020 /PRNewswire/ --The Mesothelioma Victims Center says, "We have endorsed attorney Erik Karst the founding partner of the law firm of Karst von Oiste to make certain a steel mill or factory worker with confirmed mesothelioma receives the best possible financial compensation results-nationwide. In many instances because of the Coronavirus people who have been diagnosed with mesothelioma this year might think hiring a local car accident attorney might be adequate when it comes to financial compensation-and this would be a huge mistake. If you or your husband-dad does not hire an extremely skilled lawyer who specializes in mesothelioma compensation full time the mistake could cost-you or your family hundreds of thousands of dollars or more. Erik Karst is one of the nation's leading mesothelioma attorneys and he will be able to help you.For direct access to attorney Erik Karst please call 800-714-0303."www.karstvonoiste.com

The Mesothelioma Victims Center fears that 2020 may go down as one of the worst years for mesothelioma compensation in decades for former steel mill or factory workers who have this rare cancer caused by asbestos exposure because people like this may have initially been diagnosed with the Coronavirus. Symptoms of mesothelioma and the Coronavirus include pneumonia, high fever, and shortness of breath. In other words- the symptoms are almost identical as they would be happy to discuss at 800-714-0303.

The group says, "If your husband or dad had significant exposure to asbestos at a steel mill, a factory or as a skilled trades worker maintaining a facility like this and he has been complaining about shortness of breath, or he is in the hospital with pneumonia-please tell his physicians about his asbestos exposure. If the doctors take a look-and determine it might be mesothelioma or possible mesothelioma based on an MRI or CT scan--please call 800-714-0303 for direct access to attorney Erik Karst to get a game plan. Financial compensation for people with mesothelioma might exceed a million dollars. Financial compensation for a person with mesothelioma who gets misdiagnosed with the Coronavirus is zero. We are advocates for people with mesothelioma and our top priority for people like this is they get the best compensation results."https://MesotheliomaVictimsCenter.Com

Each year about 3000 US citizens will be diagnosed with mesothelioma. Mesothelioma is caused by exposure to asbestos. High-risk work groups for exposure to asbestos include US Navy Veterans, power plant workers, shipyard workers, oil refinery workers, steel mill workers, miners, manufacturing workers, pulp or paper mill workers, plumbers, electricians, auto mechanics, machinists, construction workers, railroad workers, and firemen. Typically, the exposure to asbestos for these types of workers occurred in the 1950's, 1960's, 1970's, or 1980's.https://MesotheliomaVictimsCenter.Com

The states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

However, based on the calls the Mesothelioma Victims Center receives a steel mill or factory worker with mesothelioma could live in any state including New York, Florida, California, Texas, Illinois, Ohio, Iowa, Indiana, Missouri, North Carolina, Kentucky, Tennessee, Georgia, Mississippi, Alabama, Oklahoma, Arkansas, Kansas, Nebraska, North Dakota, Wyoming, Colorado, New Mexico, Utah, Nevada, Arizona, Idaho, or Alaska.www.karstvonoiste.com/

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer:https://www.cancer.gov/types/mesothelioma

Media contact: Michael Thomas [emailprotected]800-714-0303

SOURCE Mesothelioma Victims Center

https://MesotheliomaVictimsCenter.Com

Follow this link:

Mesothelioma Victims Center Has Endorsed Attorney Erik Karst of Karst von Oiste to Make Certain a Steel Mill or Factory Worker with Mesothelioma --...

TCR2’s T-cell therapy curbs solid tumors in early phase 1 readout – FierceBiotech

The first data are in for TCR2 Therapeutics lead program, and they look good. The T-cell therapy shrank tumors in five patients with mesothelin-expressing cancers, with two patients seeing enough shrinkage to be considered partial responders.

The data come from the first five patients in the phase 1 part of a phase 1/2 study. Although this portion of the study was geared to gauge safety and arrive at a dose for the phase 2 part, the company is encouraged by the results. Its developing the treatment, dubbed TC-210, for patients whose cancers express mesothelin, a protein that TCR2 CEO Garry Menzel calls an ideal cancer target. Mesothelin is expressed in high levels in several cancers and in low levels in healthy tissue.

Of the five patients, one had ovarian cancer and four had mesothelioma, a cancer of the mesotheliumthe thin tissue that lines the lung, chest wall and abdomenwith a five-year survival rate in the single digits. Before the trial, the patients had undergone a median of five other treatments. Three had tried checkpoint inhibitors.

RELATED: TCR2 IPO hits midpoint, setting stage for trials of CAR-T rivals

These early TC-210 data suggest our approach may overcome the challenges faced by many T cell therapies in the hostile solid tumor microenvironment, said Alfonso Quints-Cardama, M.D., TCR2 chief medical officer, in a statement. Our enrolled patients have failed multiple lines of therapy, including standard chemotherapy, checkpoint inhibitors and in some cases other mesothelin-directed approaches, in indications where survival has been historically shorter than six months.

No patients suffered side effects in the brain, a concern with CAR-T and other T-cell therapies. Three of the five patients (60%) developed cytokine release syndrome (CRS), a condition that occurs when T-cell treatment activates the immune system too strongly. Two patients had mild CRS, but the third needed aggressive treatment. This patient also suffered lung inflammation (pneumonitis) earlier in the trial and died about a month after treatment from fungal sepsis that was deemed unrelated to the treatment.

The company plans to enroll about 50 patients in the phase 2 part of the trial, including those with non-small cell lung cancer and bile duct cancer as well as ovarian cancer and mesothelioma. Each group will have 10 patients, except the lung cancer group, which will have 20 patients. Some will receive TC-210 on its own, while the others will get TC-210 in combination with an PD-1-blocking antibody.

TCR2s pipeline is built on its TRuC technology, which is designed to go where other engineered T-cell approaches, such as CAR-T or T-cell receptor (TCR) therapies, cannot. For example, CAR-T has seen success in some blood cancers but has faced difficulties in solid tumors. As for other engineered TCR treatments, they rely on the antigen HLA, which is downregulated in many cancers, making them invisible to T cells.

To avoid these problems, TCR2s tech, designed by Patrick Baeuerle, Ph.D., tethers a tumor antigen-binding domain directly to the TCR complex, creating a TRuC construct that is able to recognize highly expressed tumor antigens without HLA. The full TCR is activated, which stimulates the T cell to kill the cancer cell.

Excerpt from:

TCR2's T-cell therapy curbs solid tumors in early phase 1 readout - FierceBiotech

Kansas US Navy Veterans Lung Cancer Advocate Has Endorsed the Lawyers at Karst von Oiste to Ensure a Navy Veteran in Kansas with Lung Cancer Gets…

(MENAFN - EIN Presswire)

WICHITA, KANSAS, USA, July 31, 2020 / EINPresswire.com / -- The Kansas US Navy Veterans Lung Cancer Advocate says, "We have endorsed and we recommend the lawyers at the law firm of Karst von Oiste to assist a Navy Veteran with lung cancer with possible compensation if this person had significant exposure to asbestos prior to 1982. The compensation for a person like this might be $100,000 or a lot more depending on how, where and when they were exposed to asbestos. The average person we are trying to help get identified is over 60 years old and it does not matter if they smoked cigarettes. For direct access to the lawyers at the law firm of Karst von Oiste please call 800-714-0303 anytime.

"If a family discovers their husband or dad has mesothelioma-everyone starts calling attorneys-because they know there can be significant compensation for people like this. The $30 billion dollar-asbestos trust funds were also set up for people who had heavy exposure to asbestos and who now have lung cancer. If this sounds like you or your family member please call 800-714-0303 for direct access to the lawyers at the law firm of Karst von Oiste. The law firm of Karst von Oiste is one of the nation's leading law firms for asbestos exposure lung cancer and mesothelioma and they produce significant financial compensation for their clients." [To enable links contact MENAFN]

The Kansas US Navy Veterans Lung Cancer Advocate's free services are available to people with asbestos exposure lung cancer or mesothelioma in Wichita, Overland Park, Topeka, Olathe, Lawrence or anywhere in Kansas. [To enable links contact MENAFN]

The US Navy Veterans Lung Cancer Advocate says, 'If your husband, dad, coworker or neighbor has just been diagnosed with lung cancer and you know they had significant exposure to asbestos in the navy, at a shipyard or while working at a factory, at power plant, public utility, or as a plumber, electrician welder, mechanic or any kind of skilled trades group in any state please have them call us anytime at 800-714-0303. Most people like this never get compensated-even though the asbestos trust funds were set up for them too. We are trying to change this sad fact.' [To enable links contact MENAFN]

High-risk work groups for exposure to asbestos in Kansas include Veterans of the US Navy, one of Kansas's dozen plus power plants, manufacturing workers, industrial workers, aerospace workers in Wichita, public utility workers, plumbers, electricians, welders, auto mechanics, machinists, and construction workers. Typically. the exposure to asbestos occurred in the 1950's, 1960's, 1970's, or 1980's. [To enable links contact MENAFN]

According to the American Cancer Society for nonsmokers who have been exposed to asbestos in their workplace the risk of lung cancer is five times that of unexposed workers.[To enable links contact MENAFN] .

States with the highest incidence of lung cancer include Kentucky, West Virginia, Maine, Tennessee, Mississippi, Ohio, Indiana, Louisiana, Arkansas, Missouri, North Carolina, Rhode Island, Alabama, and Delaware. However, there are people with asbestos exposure lung cancer in Kansas. [To enable links contact MENAFN]

For more information about asbestos exposure please visit the NIH's website on this topic: [To enable links contact MENAFN] .

Michael ThomasKansas US Navy Veterans Lung Cancer Advocate+1 800-714-0303email us here

Link:

Kansas US Navy Veterans Lung Cancer Advocate Has Endorsed the Lawyers at Karst von Oiste to Ensure a Navy Veteran in Kansas with Lung Cancer Gets...

Dr. Baas on the Promise of Immuno-Oncology in Mesothelioma – OncLive

Paul Baas, MD, PhD, discusses recent updates in immuno-oncology within the field of mesothelioma.

Paul Baas, MD, PhD, a professor within the Department of Thoracic Oncology at the Netherlands Cancer Institute, discusses recent updates in immuno-oncology within the field of mesothelioma.

For mesothelioma, a few interesting developments have been made in recent years, says Baas. For 50 years, chemotherapy continued to be the standard in the space. Mesothelioma is a very aggressive disease with poor survival outcomes. Recently, however, there has been an interest in examining the use of immuno-oncology drugs within the field of mesothelioma.

To this end, a few reports of this approach in the second-line setting have been reported; these reports have implied that if 1 drug is used, such as pembrolizumab(Keytruda)or nivolumab(Opdivo), they will not show a great deal of activity, says Baas. Although these findings were a bit disappointing, some data examining nivolumaband ipilimumab(Yervoy) suggest that a combination approach might yield more promising results, says Baas.

A press release issued in April 2020 from Bristol Myers Squibb announced positive results from a first-line studycomparing immune checkpoint inhibitors versus chemotherapy in patients withmesothelioma.These data will be presented at the 2020 World Lung Conference during the Presidential Symposium and might change the first-line approach for patients; this is important news for immuno-oncology, adds Baas.

Additionally, the combination of chemotherapy with durvalumab(Imfinzi) in a single-arm study showed a favorable median overall survival (OS) of 20 months; these are quite interesting findings because normally the median OS that is reported in this space is 15 months or a maximum of 16 months, concludes Baas.

Read the original:

Dr. Baas on the Promise of Immuno-Oncology in Mesothelioma - OncLive

Mesothelioma treatment Market Insight And Key Players With Forecasts Up To 2028 Bulletin Line – Bulletin Line

Global Mesothelioma treatment Market presents an in-depth review and technical research, with useful facts and figures, of the current and future state of the mesothelioma treatment market worldwide. mesothelioma treatment market provides information on emerging market opportunities and business factors, developments and evolving technologies that will fuel these growth trends. The report provides a comprehensive overview including Comparison of Definitions, Range, Use, Production and CAGR (percent), Form Segmentation, Share, Revenue Status and Outlook, Capacity, Demand, Market Drivers, Production Status, and Outlook and Opportunities, Export, Import, Growth Rate for Emerging Markets / Countries. The study provides a 360-degree overview of the industrys competitive landscape. The industry study on mesothelioma treatment assesses the main regions (countries) promising a huge market share for the 2016-2028 forecast period.

The market research study on mesothelioma treatment was collected through comprehensive primary research through interviews, surveys, and findings of experienced analysts and secondary research. The study also provides a complete qualitative and quantitative assessment by analyzing data obtained from industry analysts and market participants from mesothelioma treatment around key points in the value chain of the industry.

The regional analysis of this report covers the following regions- Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Ono Pharmaceutical Co. Ltd, Bayer AG, Teva Pharmaceuticals Industries Ltd.

Get Sample Copy of The Report @ https://www.quincemarketinsights.com/request-sample-68793?utm_source=Kalpesh&utm_medium=BL

Useful findings of this research are-

-Study of historical data.

-Analysis of existing scenarios in every domestic and national sector.

-Study of patterns, accessible knowledge and data figures.

-Use of validated project methods for the next five years.

Statistical analysis, figures and prime data included in the report contains-

-Market size (current and projected for the last few years)

-Market share analysis as per different companies)

-Market forecast)

-Demand)

-Price analysis)

-Market contributions (Size, Share according to geographical boundaries)

The report benefits Market Investigators, companies, Vendors, Buyers, Suppliers, Individual professionals and Competitive organizations

Make An Enquiry Before Purchasing Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-68793?utm_source=Kalpesh&utm_medium=BL

Market Segmentation:

ByTreatment Type:

By Route of Administration:

ByDistribution Channel:

By End User:

By Region:

North AmericaMesothelioma treatment market

EuropeMesothelioma treatment market

Asia PacificMesothelioma treatment market

Middle East & AfricaMesothelioma treatment market

South AmericaMesothelioma treatment market

Contact:Quince Market InsightsOffice No-A109Pune, Maharashtra 411028Phone: +91-9850603687/7972869557Email: [emailprotected]Web: http://www.quincemarketinsights.com

About :QMI has the most comprehensive collection of market research products and services available on the web. Deliver reports from almost all major publications and update the list on a regular basis with instant online access to the worlds broadest and most up-to-date archive of expert insights on global markets, companies, products and patterns.

Read more:

Mesothelioma treatment Market Insight And Key Players With Forecasts Up To 2028 Bulletin Line - Bulletin Line

BASF and Law Firm Agree to $72.5 Million Settlement With Mesothelioma Victims and Others – Mesothelioma.net Blog

Published on July 24, 2020

After decades of fending off mesothelioma lawsuits by denying the presence of asbestos in its talc, BASF and its long-time law firm have agreed to a $72.5 million settlement to resolve claims that theyd hidden evidence that their talc products contained the carcinogenic material. The settlement will provide compensation to thousands of people harmed by asbestos in the chemical giants product, and will also allow those who previously dropped their claims to refile them.

According to legal ethics professor Stephen Gillers of New York University Law School, mesothelioma claims against BASF have been stymied by BASFs no asbestos claims for years.The allegation is that Cahill lawyers helped BASF hide and destroy evidence of asbestos in its talc, he said.

His comments are confirmed by the plaintiffs attorneys, who said that BASF and its law firm, Cahill, Gordon & Reindel LLP, had concealed the presence of asbestos in their talc for nearly thirty years, dating back to a 1979 lawsuit that blamed the mesothelioma death of a tire worker on the companys talc. As part of the settlement in that long-ago case, testing that confirmed asbestos in BASFs talc was sealed by a confidentiality order.Ever since that time the company argued that the carcinogen was not present in its asbestos.

The resolution of the case represents years of legal wrangling between mesothelioma victims, BASF and their attorneys. In 2012 a proposed class-action suit alleging fraud on the court was dismissed but then in 2014 a federal appeals court said the defendants actions were systematic fraud designed to thwart the judicial process. The case was later dismissed on appeal but more recently a federal appeals court in Philadelphia agreed with mesothelioma victims and reopened the case.

Much of the evidence presented came during a mesothelioma lawsuit filed by the daughter of a former employee of BASF, who argued that her illness was a result of second-hand exposure to the companys talc. Her father, formerly a research scientist, gave a deposition indicating that the company had known about asbestos in its talc for years.

People who have been diagnosed with malignant mesothelioma are the victims of asbestos exposure, and in many cases the companies responsible for this exposure were well aware of the dangers that their products caused. If you or someone you love has been affected by asbestos and you need guidance, the Patient Advocates at Mesothelioma.net can help. Contact us today at 1-800-692-8608.

Learn more about and contact Terri

Read the original:

BASF and Law Firm Agree to $72.5 Million Settlement With Mesothelioma Victims and Others - Mesothelioma.net Blog

TCR Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors | DNA RNA and Cells | News…

DetailsCategory: DNA RNA and CellsPublished on Monday, 27 July 2020 12:36Hits: 584

- TC-210 TRuC-T cell monotherapy induced tumor regression in first five patients

- Two RECIST unconfirmed partial responses and two patients with stable disease through six months

- Manageable toxicity profile, with only one patient exhibiting TC-210-related non-hematologic Grade >2 toxicity

- Translational data demonstrated T cell expansion and cytokine production

CAMBRIDGE, MA, USA I July 26, 2020 I TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors. All five patients showed tumor regression including two RECIST unconfirmed partial responses (one of which remains subject to independent central review) and two patients with stable disease through six months. Translational data further demonstrated TRuC-T cell expansion and activation. A manageable toxicity profile was observed with only one patient exhibiting TC-210-related non-hematologic grade >2 toxicity and no evidence of neurotoxicity or on-target, off-tumor toxicity.

We are delighted that our very first dose of TC-210 induced consistent tumor regression and clinical benefit in heavily pre-treated cancer patients, said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2Therapeutics. There are very few options for patients with solid tumors and those expressing mesothelin represent a significant frontier of unmet medical need. While these are early data requiring further study, we are encouraged by the potential of our TRuC-T cells as we continue to enroll and treat patients with the goal of quickly finding a recommended Phase 2 dose for TC-210.

Based on my prior experience working with both TCR-T and CAR-T cells, including the FDA approval of Kymriah, observing consistent clinical benefit in patients at presumably suboptimal T cell doses is quite meaningful, said Alfonso Quints-Cardama, M.D., Chief Medical Officer of TCR2Therapeutics. These early TC-210 data suggest our approach may overcome the challenges faced by many T cell therapies in the hostile solid tumor microenvironment. Our enrolled patients have failed multiple lines of therapy, including standard chemotherapy, checkpoint inhibitors and in some cases other mesothelin-directed approaches, in indications where survival has been historically shorter than six months.

The primary objectives of the Phase 1 portion of the study are to define the safety profile of TC-210 in patients whose tumors overexpress mesothelin and to determine the recommended Phase 2 dose (RP2D). Secondary objectives include overall response rate (ORR) and disease control rate (DCR). Exploratory objectives include the assessment of expansion, tumor infiltration, and persistence of TC-210 T cells.

Summary of trial conduct, baseline characteristics and TC-210 dose:

Key clinical findings from the first five patients treated with TRuC-T cells include:

About the Phase 1/2 Clinical Trial in Advanced Mesothelin-Expressing Solid Tumors

The Phase 1/2 clinical trial (NCT03907852) is evaluating the safety and efficacy of TC-210, TCR2s T-cell receptor fusion construct directed against mesothelin. The trial is enrolling patients with mesothelin expressing NSCLC, ovarian cancer, cholangiocarcinoma, and malignant pleural/peritoneal mesothelioma. The Phase 1 dose escalation portion of the clinical trial utilizes a modified 3+3 design withfour increasing TC-210 T cell doses. At each dose, TC-210 will be tested in two separate dose levels: first without lymphodepletion and then following lymphodepleting chemotherapy. The Phase 1 portion of the clinical trial is ongoing.

In the Phase 2 portion of the clinical trial, approximately 50 patients are planned to receiveTC-210at the RP2D in four distinct cohorts according to their cancer diagnosis: NSCLC, ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Each cohort will include ten patients, except the NSCLC cohort which will include 20patients with eight patients to receive TC-210as single agent and 12 patients to receive TC-210in combination with a programmed cell death 1(PD-1)blocking antibody.

About Mesothelin-Expressing Solid Tumors

Mesothelin is a cell-surface glycoprotein highly expressed in a wide range of solid tumors, including malignant pleural/peritoneal mesothelioma, ovarian cancer, cholangiocarcinoma, breast cancer, pancreatic cancer and others. Overexpression of mesothelin is associated with poorer prognosis in some cancers due to its active role in both malignant transformation and tumor aggressiveness by promoting cancer cell proliferation, invasion, and metastasis. Of the wide range of solid tumors expressing mesothelin, non-small cell lung cancer, ovarian cancer, mesothelioma and cholangiocarcinoma represent a significant patient population up to 80,000 in the United States alone.

TCR2 Therapeutics Conference Call and Webcast

TCR2 Therapeutics will host a conference call and webcast on Monday, July 27th at 8:00am E.T. The webcast and presentation will be made available on the TCR2 Therapeutics website in the Investors section under Events at http://investors.tcr2.com/events. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

About TCR2 Therapeutics

TCR2Therapeutics Inc.is a clinical-stage immunotherapy company developing a pipeline of novel Tcell therapies for patients suffering from solid tumors or hematological malignancies.TCR2sproprietary T cell receptor (TCR) Fusion Construct Tcells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent ofhuman leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Companys lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Companys lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visitwww.tcr2.com.

SOURCE: TCR2 Therapeutics

Continued here:

TCR Therapeutics Announces RECIST Responses with First TC-210 Dose Tested in Advanced Mesothelin-Expressing Solid Tumors | DNA RNA and Cells | News...